KRW 27400.0
(-5.03%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 43 Billion KRW | 7.5% |
2022 | 40 Billion KRW | 55212.03% |
2021 | 72.31 Million KRW | -86.98% |
2020 | 555.33 Million KRW | 0.0% |
2019 | - KRW | 0.0% |
2018 | - KRW | -100.0% |
2017 | 7.62 Billion KRW | 227.76% |
2016 | 2.32 Billion KRW | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | 43 Billion KRW | 0.0% |
2024 Q2 | 43 Billion KRW | 0.0% |
2023 Q1 | 409.91 Million KRW | -98.98% |
2023 Q4 | 43 Billion KRW | 18393.67% |
2023 Q3 | 232.51 Million KRW | 28.93% |
2023 Q2 | 180.34 Million KRW | -56.01% |
2023 FY | 43 Billion KRW | 7.5% |
2022 Q1 | - KRW | -100.0% |
2022 Q4 | 40 Billion KRW | 4358.92% |
2022 Q3 | 897.07 Million KRW | 0.0% |
2022 Q2 | - KRW | 0.0% |
2022 FY | 40 Billion KRW | 55212.03% |
2021 FY | 72.31 Million KRW | -86.98% |
2021 Q2 | - KRW | 0.0% |
2021 Q4 | 72.31 Million KRW | 0.0% |
2021 Q3 | - KRW | 0.0% |
2021 Q1 | - KRW | 0.0% |
2020 FY | 555.33 Million KRW | 0.0% |
2019 FY | - KRW | 0.0% |
2018 FY | - KRW | -100.0% |
2017 FY | 7.62 Billion KRW | 227.76% |
2016 FY | 2.32 Billion KRW | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Sam Chun Dang Pharm. Co., Ltd | 16 Billion KRW | -168.75% |
Hyundai Bioscience Co., Ltd. | 32.43 Million KRW | -132485.101% |
ST Pharm Co.,Ltd. | 159.68 Billion KRW | 73.073% |
Cellid, Co., Ltd. | 6.48 Billion KRW | -562.841% |